Key facts
- Notable investors include Lazio Innova, European Commission.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Netabolics
- ·The full record, as it builds
Funding rounds
No funding rounds for Netabolics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Netabolics
Developer of artificial intelligence-driven biosimulation technology designed to support drug discovery and biological target identification in pharmaceutical research. The company builds computational platforms that combine genome-scale biological modeling, machine learning, and cellular simulation to analyze disease mechanisms and predict drug response, enabling researchers to analyze disease mechanisms and support drug discovery using AI-based biosimulation tools.
- Sector
- Healthcare
- HQ
- Rome, Italy
- Founded
- 2020
- Employees
- 2
- Website
- netabolics.ai/
- Ownership
- Privately Held (backing)
Netabolics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Netabolics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Netabolics in its N-PORT filings yet. We sweep new filings monthly.